(Q42782227)
Statements
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy (English)
Sammy Saab
Michael McTigue
Richard S Finn
1 December 2010
scientific article published on December 2010